Exhibit 16.1
March 24, 2021
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-7561
Dear Sirs/Madams:
We have read Item 16F of Form 20-F of ProQR Therapeutics N.V. for the year ended December 31, 2020 to be filed on or around March 24, 2021 and have the following comments:
1. | We agree with the statements made in the second, third and fourth paragraphs of Item 16F for which we have a basis on which to comment on, and we agree with, the disclosures. |
2. | We have no basis on which to agree or disagree with other statements of the registrant contained therein. |
Yours sincerely,
/s/ Deloitte Accountants B.V.
Amsterdam, The Netherlands